AaronPaulRapoportMD

Professor of Medicine, University MD School of Medicine

Overview of Dr. Rapoport

Dr. Aaron Rapoport is a hematologist in Baltimore, MD and is affiliated with University of Maryland Medical Center. He received his medical degree from Harvard Medical School and has been in practice 31 years. Dr. Rapoport accepts several types of health insurance, listed below. He is one of 12 doctors at University of Maryland Medical Center who specialize in Hematology. He has more than 100 publications and over 500 citings.

Office
22 S Greene St
Baltimore, MD 21201
Book by Phone+1(443) 348-0188

Fax+1 410-328-1975

Education & Training

University of RochesterFellowship, Hematology and Medical Oncology, 1989 - 1993
University of RochesterResidency, Internal Medicine, 1986 - 1989
Harvard Medical SchoolClass of 1986

Certifications & Licensure

PA State Medical License 1993 - Present
MD State Medical License 1997 - 2025
NY State Medical License 1987 - 1998
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
America's Top Doctors Castle Connolly, 2012-2014
America's Top Doctors for Cancer Castle Connolly, 2011-2013
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 1998 Sep 01
Completed
Phase 2
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia Start of enrollment: 1999 Mar 01
Completed
Phase 2
Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma Start of enrollment: 2001 Dec 01
Completed
Phase 1, Phase 2
Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma Start of enrollment: 2006 Dec 01
Completed
Phase 1, Phase 2
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma Start of enrollment: 2011 May 10
Completed
Phase 2
Redirected Auto T Cells for Advanced Myeloma Start of enrollment: 2011 May 13
Completed
Phase 2
CT Antigen TCR-Engineered T Cells for Myeloma Start of enrollment: 2013 Oct 15
Terminated
Phase 1, Phase 2
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma Start of enrollment: 2014 Jun 05
Completed
Phase 1
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Coordinated antiviral immune response in a patient with myeloma and systemic adenovirus infection post-BCMA CAR T cells.
Mehmet H Kocoglu, Tim Luetkens, Jacqueline T Bork, John Baddley, Destiny Omili
Blood Advances. 2024-11-26
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Michael D Jain, Jay Y Spiegel, Loretta J Nastoupil, John Tamaresis, Armin Ghobadi
Journal of Clinical Oncology. 2024-10-20
Outcomes of Patients with Myeloid Malignancies and Cardiovascular Disease Undergoing Allogeneic Stem Cell Transplantation.
Gabriela Sanchez-Petitto, Olga Goloubeva, James Childress, Tahreem Iqbal, Jack Masur
Acta Haematologica. 2024-08-27

Journal Articles

Final Outcomes of Escalated Melphalan 280 mg/m2 with Amifostine Cytoprotection Followed Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: High C...
Neal Flomenberg, Dianna S Howard, Barry R Meisenberg, Parameswaran Hari, Gordon L Phillips, David H Vesole, Jasleen Randhawa, Aaron P Rapoport, Nature

Lectures

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

University of Maryland Greenebaum Comprehensive Cancer Center Offers Novel Next-Generation CAR T-cell Therapy for B-cell Lymphomas in First-in-Human Clinical TrialNovember 25th, 2024
Maryland Governor's Cancer in Remission; Treatment ContinuesNovember 17th, 2015
Immunotherapy Is the Future of Cancer Research: 70% of Multiple Myeloma Patients Find Recovery with New TreatmentJuly 20th, 2015
Join now to see all

Grant Support

Immunotherapy After ASCT For MM Using Htert Vaccination + Vaccine-Primed T CellsNational Cancer Institute2007–2009
Immune Responses To T-Cell Expansion + PCV ImmunizationNational Cancer Institute2004–2005

Professional Memberships

American College of Physicians - ACP
Member

Insurance Accepted

Aetna Choice POS II
BCBS Blue Card PPO
CareFirst BlueChoice Advantage
CareFirst BlueChoice Network POS
CareFirst BluePreferred PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
Health Alliance PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment